BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 21479248)

  • 21. IP-10 response to RD1 antigens might be a useful biomarker for monitoring tuberculosis therapy.
    Kabeer BS; Raja A; Raman B; Thangaraj S; Leportier M; Ippolito G; Girardi E; Lagrange PH; Goletti D
    BMC Infect Dis; 2011 May; 11():135. PubMed ID: 21595874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined use of Quantiferon and HBHA-based IGRA supports tuberculosis diagnosis and therapy management in children.
    Sali M; Buonsenso D; D'Alfonso P; De Maio F; Ceccarelli M; Battah B; Palucci I; Chiacchio T; Goletti D; Sanguinetti M; Valentini P; Delogu G
    J Infect; 2018 Dec; 77(6):526-533. PubMed ID: 30267797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of T-cell interferon-gamma release assays for Mycobacterium tuberculosis-specific antigens in patients with active and latent tuberculosis.
    Kobashi Y; Shimizu H; Ohue Y; Mouri K; Obase Y; Miyashita N; Oka M
    Lung; 2010 Aug; 188(4):283-7. PubMed ID: 20422203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Protective and therapeutic efficacy of Mycobacterium smegmatis expressing HBHA-hIL12 fusion protein against Mycobacterium tuberculosis in mice.
    Zhao S; Zhao Y; Mao F; Zhang C; Bai B; Zhang H; Shi C; Xu Z
    PLoS One; 2012; 7(2):e31908. PubMed ID: 22363768
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevance of QuantiFERON-TB Gold Plus and Heparin-Binding Hemagglutinin Interferon-γ Release Assays for Monitoring of Pulmonary Tuberculosis Clearance: A Multicentered Study.
    Chedid C; Kokhreidze E; Tukvadze N; Banu S; Uddin MKM; Biswas S; Russomando G; Acosta CCD; Arenas R; Ranaivomanana PP; Razafimahatratra C; Herindrainy P; Rakotonirina J; Raherinandrasana AH; Rakotosamimanana N; Hamze M; Ismail MB; Bayaa R; Berland JL; De Maio F; Delogu G; Endtz H; Ader F; Goletti D; Hoffmann J
    Front Immunol; 2020; 11():616450. PubMed ID: 33603746
    [TBL] [Abstract][Full Text] [Related]  

  • 26.
    Mpande CAM; Steigler P; Lloyd T; Rozot V; Mosito B; Schreuder C; Reid TD; Bilek N; Ruhwald M; Andrews JR; Hatherill M; Little F; Scriba TJ; Nemes E
    Front Immunol; 2021; 12():712480. PubMed ID: 34526988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A Mycobacterium tuberculosis Dormancy Antigen Differentiates Latently Infected Bacillus Calmette-Guérin-vaccinated Individuals.
    Peña D; Rovetta AI; Hernández Del Pino RE; Amiano NO; Pasquinelli V; Pellegrini JM; Tateosian NL; Rolandelli A; Gutierrez M; Musella RM; Palmero DJ; Gherardi MM; Iovanna J; Chuluyan HE; García VE
    EBioMedicine; 2015 Aug; 2(8):884-90. PubMed ID: 26425695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Contribution of a heparin-binding haemagglutinin interferon-gamma release assay to the detection of Mycobacterium tuberculosis infection in HIV-infected patients: comparison with the tuberculin skin test and the QuantiFERON-TB Gold In-tube.
    Wyndham-Thomas C; Dirix V; Schepers K; Martin C; Hildebrand M; Goffard JC; Domont F; Libin M; Loyens M; Locht C; Van Vooren JP; Mascart F
    BMC Infect Dis; 2015 Feb; 15():59. PubMed ID: 25886172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In vivo and in vitro effects of antituberculosis treatment on mycobacterial interferon-gamma T cell response.
    Sauzullo I; Mengoni F; Lichtner M; Massetti AP; Rossi R; Iannetta M; Marocco R; Del Borgo C; Soscia F; Vullo V; Mastroianni CM
    PLoS One; 2009; 4(4):e5187. PubMed ID: 19365543
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Lack of Response to HBHA in HIV-Infected Patients with Latent Tuberculosis Infection.
    Delogu G; Vanini V; Cuzzi G; Chiacchio T; De Maio F; Battah B; Pinnetti C; Sampaolesi A; Antinori A; Goletti D
    Scand J Immunol; 2016 Dec; 84(6):344-352. PubMed ID: 27636597
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Key role of effector memory CD4+ T lymphocytes in a short-incubation heparin-binding hemagglutinin gamma interferon release assay for the detection of latent tuberculosis.
    Wyndham-Thomas C; Corbière V; Dirix V; Smits K; Domont F; Libin M; Loyens M; Locht C; Mascart F
    Clin Vaccine Immunol; 2014 Mar; 21(3):321-8. PubMed ID: 24391135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Two-Hit
    Adankwah E; Lundtoft C; Güler A; Franken KLMC; Ottenhoff THM; Mayatepek E; Owusu-Dabo E; Phillips RO; Nausch N; Jacobsen M
    Front Immunol; 2019; 10():1518. PubMed ID: 31333654
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnostic Accuracy of Early Secretory Antigenic Target-6-Free Interferon-gamma Release Assay Compared to QuantiFERON-TB Gold In-tube.
    Nemes E; Abrahams D; Scriba TJ; Ratangee F; Keyser A; Makhethe L; Erasmus M; Mabwe S; Bilek N; Rozot V; Geldenhuys H; Hatherill M; Lempicki MD; Holm LL; Bogardus L; Ginsberg AM; Blauenfeldt T; Smith B; Ellis RD; Loxton AG; Walzl G; Andersen P; Ruhwald M
    Clin Infect Dis; 2019 Oct; 69(10):1724-1730. PubMed ID: 30668657
    [TBL] [Abstract][Full Text] [Related]  

  • 34. QuantiFERON-TB Gold assay for the diagnosis of latent tuberculosis infection.
    Manuel O; Kumar D
    Expert Rev Mol Diagn; 2008 May; 8(3):247-56. PubMed ID: 18598104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of the CD4 and CD8 T-cell response in the QuantiFERON-TB Gold Plus kit.
    Petruccioli E; Chiacchio T; Pepponi I; Vanini V; Urso R; Cuzzi G; Barcellini L; Palmieri F; Cirillo DM; Ippolito G; Goletti D
    Int J Mycobacteriol; 2016 Dec; 5 Suppl 1():S25-S26. PubMed ID: 28043588
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Distinct effector memory CD4+ T cell signatures in latent Mycobacterium tuberculosis infection, BCG vaccination and clinically resolved tuberculosis.
    Adekambi T; Ibegbu CC; Kalokhe AS; Yu T; Ray SM; Rengarajan J
    PLoS One; 2012; 7(4):e36046. PubMed ID: 22545156
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of CD8 T-cell in immune response to tuberculosis-specific antigen in QuantiFERON-TB Gold Plus.
    Tsuyuzaki M; Igari H; Okada N; Suzuki K
    J Infect Chemother; 2020 Jun; 26(6):570-574. PubMed ID: 32067903
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive value of a whole blood IFN-gamma assay for the development of active tuberculosis disease after recent infection with Mycobacterium tuberculosis.
    Diel R; Loddenkemper R; Meywald-Walter K; Niemann S; Nienhaus A
    Am J Respir Crit Care Med; 2008 May; 177(10):1164-70. PubMed ID: 18276940
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparative analysis of whole-blood interferon-γ and flow cytometry assays for detecting post-treatment immune responses in patients with active tuberculosis.
    Kim CH; Choi KJ; Yoo SS; Lee SY; Won DI; Lim JO; Cha SI; Park JY; Lee J
    Cytometry B Clin Cytom; 2014 Jul; 86(4):236-43. PubMed ID: 23959689
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immune profiling of Mycobacterium tuberculosis-specific T cells in recent and remote infection.
    Mpande CAM; Rozot V; Mosito B; Musvosvi M; Dintwe OB; Bilek N; Hatherill M; Scriba TJ; Nemes E;
    EBioMedicine; 2021 Feb; 64():103233. PubMed ID: 33610126
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.